FDA Novo Nordisk - Search News

FDA Declares Shortage of Novo Nordisk's Wegovy, Ozempic

FiercePharma · 14h

Compounders sue FDA again over declaring end of shortage for Novo's semaglutide

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.

Hosted on MSN · 4d

FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

The Washington Post on MSN · 4d

FDA says Ozempic shortage is over, chilling boom in off-brand versions

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the end to the booming market for cheaper versions made by pharmacies.

Novo Nordisk’s stock is rallying

MarketWatch on MSN · 16h

Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

The Motley Fool on MSN · 4d

Why Novo Nordisk Stock Popped on Friday

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ) that's also probably bad news for Hims & Hers Health ( HIMS -17.80%).

Wall Street Journal · 20h

Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

1d

Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

12hon MSN

Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results